VEGFR-3-IN-1|cas:2756668-73-0|西域试剂

VEGFR-3-IN-1,98.55%

产品编号：Bellancom-132305| CAS NO：2756668-73-0| 分子式：C₂₉H₂₉ClF₃N₇OS| 分子量：616.10

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-132305		￥5000.00	杭州北京（现货）
Bellancom-132305		￥8500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

VEGFR-3-IN-1

产品介绍

VEGFR-3-IN-1 是一种有效的高选择性 VEGFR3 抑制剂，其 IC₅₀ 为 110.4 nM。VEGFR-3-IN-1 通过使 VEGFR3 信号通路失活，显著抑制 VEGF-C 诱导人真皮淋巴管内皮细胞 (HDLEC)、MDA-MB-231 和 MDA-MB-436 细胞的增殖和迁移，并且能有效抑制乳腺癌的生长。

生物活性

VEGFR-3-IN-1 is a potent and selective VEGFR3 inhibitor with an IC₅₀ of 110.4 nM. VEGFR-3-IN-1 significantly inhibits proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231, and MDA-MB-436 cells by inactivating the VEGFR3 signaling pathway, and also effectively inhibits breast cancer growth.

体外研究

VEGFR-3-IN-1 (compound 38k) exhibits a significantly higher antiproliferative activity on MDA-MB-231 and MDA-MB-436 cells than 10 (IC₅₀ > 50 μM), with IC₅₀ values of 2.22 and 3.50 μM, respectively.
VEGFR-3-IN-1 markedly suppresses the phosphorylation of VEGFR3 and its downstream proteins in a dose-dependent manner.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	MDA-MB-231 and MDA-MB-436 cells
Concentration:	100 nM
Incubation Time:	48 hours
Result:	Exerted antimigration and antiproliferative activities through targeting VEGFR3 in MDA-MB-231 and MDA-MB-436 cells.

Western Blot Analysis

Cell Line:	HDLEC cells
Concentration:	10-500 nM
Incubation Time:
Result:	Antilymphangiogenic activities of VEGFR-3-IN-1 by suppressing the expression of VEGFR3.

体内研究
(In Vivo)

VEGFR-3-IN-1 (50, 25 mg/kg; p.o.) reduces the tumor volume, and displays the strongest inhibitory activity in mice, with a growth inhibition rate of 61.9%.
VEGFR-3-IN-1 (10 mg/kg; p.o.) treatment shows the C_max, AUC_0-t, AUC_0-∞ and t_1/2 values of 420 ng/mL, 9219 ng h/mL, 12304 ng h/mL and 16 hours, respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice (carrying xenografted BC)
Dosage:	50 mg/kg
Administration:	P.o.;once
Result:	Reduced the tumor volume, and displayed the strongest inhibitory activity in mice.

Animal Model:	Sprague-Dawley (SD) rats
Dosage:	10 mg/kg
Administration:	P.o. (Pharmacokinetic Analysis)
Result:	The C_max, AUC_0-t, AUC_0-∞ and t_1/2 were 420 ng/mL, 9219 ng h/mL, 12304 ng h/mL and 16 hours, respectively.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice (carrying xenografted BC)
Dosage:	50 mg/kg
Administration:	P.o.;once
Result:	Reduced the tumor volume, and displayed the strongest inhibitory activity in mice.

Animal Model:	Sprague-Dawley (SD) rats
Dosage:	10 mg/kg
Administration:	P.o. (Pharmacokinetic Analysis)
Result:	The C_max, AUC_0-t, AUC_0-∞ and t_1/2 were 420 ng/mL, 9219 ng h/mL, 12304 ng h/mL and 16 hours, respectively.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice (carrying xenografted BC)
Dosage:	50 mg/kg
Administration:	P.o.;once
Result:	Reduced the tumor volume, and displayed the strongest inhibitory activity in mice.

Animal Model:	Sprague-Dawley (SD) rats
Dosage:	10 mg/kg
Administration:	P.o. (Pharmacokinetic Analysis)
Result:	The C_max, AUC_0-t, AUC_0-∞ and t_1/2 were 420 ng/mL, 9219 ng h/mL, 12304 ng h/mL and 16 hours, respectively.

性状

Solid

溶解性数据

In Vitro:

DMSO : 12.5 mg/mL (20.29 mM; ultrasonic and warming and adjust pH to 6 with HCl and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6231 mL	8.1156 mL	16.2311 mL
5 mM	0.3246 mL	1.6231 mL	3.2462 mL
10 mM	0.1623 mL	0.8116 mL	1.6231 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式